Beta Bionics, INC Form 4 insider transactions

Beta Bionics, Inc. (BBNX) CFO Stephen Feider amended a Form 4 filing to correct share counts related to option exercises and sales executed under a Rule 10b5-1 trading plan.

Beta Bionics, Inc. (BBNX) Chief Financial Officer, Stephen Feider, reported transactions involving the sale of company common stock and the acquisition of stock options under a pre-arranged trading plan.

Beta Bionics Chief Commercial Officer Mark Hopman sold 1,258 shares of common stock for approximately $18,875 under a pre-arranged Rule 10b5-1 trading plan.

Beta Bionics, Inc. reports that Director Christy Jones sold 1,406 shares of common stock on June 24, 2026, as part of a pre-arranged Rule 10b5-1 trading plan.

Chief Commercial Officer Mark Hopman sold 275 shares of Beta Bionics common stock under a pre-arranged 10b5-1 trading plan.

Director Christy Jones sold 2,811 shares of Beta Bionics, Inc. common stock on June 4, 2026, via a Rule 10b5-1 trading plan.

Chief Product Officer Mike Mensinger sold 4,378 shares of Beta Bionics to cover tax obligations related to RSU vesting.

Chief Commercial Officer Mark Hopman sold 5,329 shares of Beta Bionics to satisfy tax withholding obligations.

Chief Medical Officer Steven Jon Russell sold 4,222 shares of Beta Bionics common stock to satisfy tax withholding obligations.

CFO Stephen Feider sold 6,676 shares of Beta Bionics to satisfy tax withholding obligations related to RSU vesting.

CEO Sean Saint sold 16,872 shares of Beta Bionics common stock to satisfy tax withholding obligations related to RSU vesting.

Beta Bionics, Inc. reports a Form 4 filing detailing a transaction by Director Michel Gerard J, acquiring 16,965 shares of common stock.

Beta Bionics, Inc. Director Christy Jones reported a sale of 1,998 shares of common stock under a pre-arranged 10b5-1 trading plan and an award of 16,965 restricted stock units.

Maria Palasis, a Director at Beta Bionics, Inc., acquired 16,965 shares of common stock through a restricted stock unit award.

Beta Bionics, Inc. reports that Director Danny L. Dearen acquired 16,965 shares of common stock on May 21, 2026, through a restricted stock unit award.

Beta Bionics, Inc. reports that Director Sean Carney acquired 16,965 shares of common stock through a restricted stock unit award.

Beta Bionics, Inc. Director Adam Lezack reported transactions involving common stock and restricted stock units.

Beta Bionics' Chief Commercial Officer, Mark Hopman, filed a Form 4 detailing future sales of common stock.

Beta Bionics' Chief Medical Officer, Steven Jon Russell, sold 1,025 shares of common stock to cover tax withholding obligations.

Beta Bionics' Chief Product Officer, Mike Mensinger, filed an amended Form 4 to correct the number of shares in a recent stock option grant.

Beta Bionics' Chief Medical Officer, Steven Jon Russell, filed an amended Form 4 to correct the number of shares in a recent employee stock option grant.

Beta Bionics, Inc. CEO Sean Saint filed an amended Form 4 to correct the number of shares in a recent employee stock option grant.

Beta Bionics' Chief Commercial Officer, Mark Hopman, filed an amended Form 4 to correct the number of shares in a recent stock option grant.

Beta Bionics' CFO, Stephen Feider, acquired 110,342 employee stock options with an exercise price of $12.63, vesting over 36 months.

Beta Bionics' Chief Commercial Officer, Mark Hopman, sold 353 shares of common stock for $11.57 per share under a pre-arranged 10b5-1 plan.

Beta Bionics Chief Commercial Officer Mark Hopman reported the acquisition of restricted stock units and stock options, alongside a sale of shares to cover tax obligations.

Beta Bionics' Chief Medical Officer, Steven Jon Russell, reported the acquisition of restricted stock units and stock options, alongside a sale of shares to cover tax obligations.

Beta Bionics Chief Product Officer Mike Mensinger reported the acquisition of restricted stock units and stock options, alongside a sale of shares to cover tax obligations.

Beta Bionics CFO Stephen Feider reported the acquisition of restricted stock units and stock options, alongside a sale of shares to cover tax obligations.

Beta Bionics CEO Sean Saint reported the acquisition of restricted stock units and stock options, alongside a sale of shares to cover tax obligations.